Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wikstrand

Showing results (261-270 of 277) with videos related to

Pageof 28
Sort By:
The American Journal of Pathology|March 1, 1988
Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-mycH S Friedman, P C Burger, S H Bigner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapyVidyalakshmi Chandramohan, Xuhui Bao, Stephen T Keir, et al.
Nuclear Medicine and Biology|October 1, 2011
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMichael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, et al.
BMC Cancer|September 3, 2010
MRP3: a molecular target for human glioblastoma multiforme immunotherapyChien-Tsun Kuan, Kenji Wakiya, James E Herndon, et al.
Clinical Pharmacology and Therapeutics|November 7, 2013
An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudyJ A Batty, A S Hall, H L White, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsJ H Sampson, L E Crotty, S Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodiesWeilian Yang, Gong Wu, Rolf F Barth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targetingJohn C Sok, Francesca M Coppelli, Sufi M Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4Weilian Yang, Rolf F Barth, Gong Wu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2004
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R)Enkhtsetseg Purev, Dewei Cai, Eric Miller, et al.
Pageof 28

Showing results (261-270 of 277) with videos related to

Sort By:
Pageof 28
The American Journal of Pathology|March 1, 1988
Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-mycH S Friedman, P C Burger, S H Bigner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapyVidyalakshmi Chandramohan, Xuhui Bao, Stephen T Keir, et al.
Nuclear Medicine and Biology|October 1, 2011
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMichael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, et al.
BMC Cancer|September 3, 2010
MRP3: a molecular target for human glioblastoma multiforme immunotherapyChien-Tsun Kuan, Kenji Wakiya, James E Herndon, et al.
Clinical Pharmacology and Therapeutics|November 7, 2013
An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudyJ A Batty, A S Hall, H L White, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsJ H Sampson, L E Crotty, S Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodiesWeilian Yang, Gong Wu, Rolf F Barth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targetingJohn C Sok, Francesca M Coppelli, Sufi M Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4Weilian Yang, Rolf F Barth, Gong Wu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2004
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R)Enkhtsetseg Purev, Dewei Cai, Eric Miller, et al.
Pageof 28